The Firm represented Woori Blackstone Korea Opportunity Private Equity Fund I, a Korean private equity fund operated under joint general partnership between The Blackstone Group and Woori Private Equity, in its minority investment in NS Shopping Co., Ltd., the 5^th largest home shopping company in Korea. The investment was jointly made with Shinhan BNP Paribas Asset Management Co., Ltd.

More >>

Davis Polk advised Deutsche Bank AG, Singapore Branch as the exclusive dealer manager in connection with a cash tender offer by China Oriental Group Company Limited for up to $200 million of its outstanding $300 million 7% senior notes due 2017 and $550 million 8% senior notes due 2015.

More >>

Simpson Thacher recently represented Credit Suisse (Hong Kong) Limited and Morgan Stanley Asia Limited as joint placement agents in connection with the private placement of convertible preference shares by Alibaba Group Holding Limited, which raised approximately $1.8 billion. The placement of convertible preference shares was part of a financing package that is the largest private financing for a private sector Chinese company, and the largest ever non-LBO private financing for a technology company globally.

More >>

Paul Hastings, a leading global law firm, announced today that it represented China SCE Property Holdings Limited (“China SCE”), a company listed on the Hong Kong Stock Exchange, on its issuance of senior notes in the aggregate principal amount of US$200 million. China SCE is a leading property developer based in China’s Fujian province.

More >>

Law firm Loeb & Loeb LLP, which opened an office in Hong Kong in October in association with Pang & Co., has already closed two significant Hong Kong initial public offerings for Pegasus Entertainment Holdings Limited and Sunley Holdings Limited. These transactions are two of just four IPOs that have closed in the region in the last two months.

More >>

Herbert Smith Freehills has recently advised China National Offshore Oil Corporation (CNOOC) on its entry into a Heads of Agreement (HOA) with BG Group for the acquisition of major interests in the Queensland Curtis LNG (QCLNG) project in Australia for $1.93 billion and the sale of liquefied natural gas (LNG) from BG Group’s global LNG portfolio. Fully-termed transaction agreements are expected to be executed in the first half of 2013, and upon closing, CNOOC will reimburse BG Group for its share of QCLNG project capital expenditures incurred from 1 January 2012.

More >>

The notes were listed on the Singapore Stock Exchange Securities Trading Limited with Citigroup and HSBC acting as joint lead managers for the issuance of the securities.

More >>

King & Wood Mallesons had advised BG Group on its entry into a Heads of Agreement (HOA) for the sale of certain interests in the Queensland Curtis LNG (QCLNG) project to China National Offshore Oil Corporation (CNOOC) for $1.93 billion (marking one of China’s biggest recentinvestments into Australia), and the sale of liquefied natural gas (LNG) from BG Group’s global LNG portfolio. Fully-termed transaction agreements are expected to be executed in the first half of 2013 and, on closing, CNOOC will reimburse BG Group for its share of QCLNG project capital expenditures incurred from 1 January 2012.

More >>

Morrison & Foerster is representing Shanghai Fosun Pharmaceutical (Group) Co., Ltd. in its US$512 million initial public offering on the Hong Kong Stock Exchange today. Fosun Pharma is the third largest Hong Kong IPO deal this year, and the first significant successful new listing since July. UBS AG, China International Capital Corp., J.P. Morgan and Deutsche Bank AG acted as the joint global coordinators in the deal.

More >>

Herbert Smith Freehills has advised UBS AG, China International Capital Corporation, J.P. Morgan Securities (Asia Pacific) Limited, Deutsche Bank AG, Agricultural Bank of China International and Haitong International as underwriters on the HK$3.97 billion (US$509 million) initial public offering (IPO) of Shanghai Fosun Pharmaceutical Group Co. Ltd (“Fosun Pharma”) on the main board of the Hong Kong Stock Exchange and Rule 144A/Regulation S global offering on 30 October, 2012. The deal marks one of the largest IPOs in the world’s pharmaceutical industry since June 2011 and one of the few recent significant new listings in Hong Kong since July this year.

More >>